Payment overview · 2025
General Payments
$263.47
12 reported records · 7 companies
Healthcare provider profile · identity verified
Lisa A. Abbott, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MANSFIELD, TX · NPI 1700847779
Verified facts
What the public records show
CMS Open Payments records show Lisa A. Abbott, M.D. received $263.47 in general payments during 2025 across 12 reported records.
Inspire Medical Systems, Inc. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $63.47 | 24.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.46 | 21.4% | 3 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $48.98 | 18.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.10 | 16.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.27 | 7.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.39 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.80 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.47 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $63.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $48.98 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 860 | 276 |
| Amlodipine Besylate | Amlodipine Besylate | 472 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 143 |
| Losartan Potassium | Losartan Potassium | 373 | 120 |
| Gabapentin | Gabapentin | 310 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 92 |
| Trazodone Hcl | Trazodone Hcl | 267 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 74 |
| Sertraline Hcl | Sertraline Hcl | 244 | 74 |
| Metformin Hcl | Metformin Hcl | 234 | 80 |
| Lisinopril | Lisinopril | 228 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 206 | 58 |
| Omeprazole | Omeprazole | 204 | 77 |
| Montelukast Sodium | Montelukast Sodium | 175 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 159 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 47 |
| Tramadol Hcl | Tramadol Hcl | 155 | 48 |
| Bupropion Xl | Bupropion Hcl | 151 | 46 |
| Simvastatin | Simvastatin | 139 | 41 |
| Meloxicam | Meloxicam | 138 | 52 |
| Ozempic | Semaglutide | 136 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 44 |
| Furosemide | Furosemide | 124 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 42 |
| Potassium Chloride | Potassium Chloride | 111 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 39 |
| Methylprednisolone | Methylprednisolone | 108 | 93 |
| Eliquis | Apixaban | 101 | 26 |
| Temazepam | Temazepam | 95 | 17 |
| Mounjaro | Tirzepatide | 89 | 18 |
| Atenolol | Atenolol | 88 | 29 |
| Lovastatin | Lovastatin | 87 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 84 | 30 |
| Jardiance | Empagliflozin | 82 | 22 |
| Carvedilol | Carvedilol | 81 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 24 |
| Alprazolam | Alprazolam | 80 | 24 |
| Methocarbamol | Methocarbamol | 78 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 63 |
| Celecoxib | Celecoxib | 73 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 73 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 27 |
| Alendronate Sodium | Alendronate Sodium | 68 | 20 |
| Risedronate Sodium | Risedronate Sodium | 68 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 20 |
| Estradiol | Estradiol | 66 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 18 |
| Glimepiride | Glimepiride | 64 | 22 |
| Prednisone | Prednisone | 64 | 37 |
| Valsartan | Valsartan | 63 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 21 |
| Clonazepam | Clonazepam | 61 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 46 |
| Cefuroxime | Cefuroxime Axetil | 55 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 14 |
| Fenofibrate | Fenofibrate | 48 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 16 |
| Pregabalin | Pregabalin | 39 | 17 |
| Januvia | Sitagliptin Phosphate | 37 | 13 |
| Allopurinol | Allopurinol | 36 | 13 |
| Prolia | Denosumab | 36 | 22 |
| Topiramate | Topiramate | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 19 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Azithromycin | Azithromycin | 32 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 19 |
| Mometasone Furoate | Mometasone Furoate | 30 | 25 |
| Ramipril | Ramipril | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Linzess | Linaclotide | 24 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 17 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Nystatin | Nystatin | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.47 · 12 records | Inspire Medical Systems, Inc. | ABRYSVO, COMIRNATY, ETERNA, EVENITY, INSPIRE, PREVNAR 20, Prospera, SOMAVERT, TRELEGY ELLIPTA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error